跳至主要内容
临床试验/NCT01492114
NCT01492114已完成3 期

Double-blind Cross-over Randomised Controlled Trial on the Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.

University of Turin, Italy2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2011年7月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
40
试验地点
2
主要终点
C-reactive protein

研究概览

简要总结

This research will investigate the hypothesis that resveratrol when given orally to healthy adult smokers induces a decrease in the inflammatory and oxidative mediators which characterize the low-grade systemic inflammatory state and the oxidants-antioxidants imbalance of tobacco users.

详细描述

The effect of resveratrol in humans is still not well defined. The number of studies on resveratrol has increased extraordinarily since 1997, when its anticancer effect has been reported. However, most of these studies are in-vitro or animal studies. Preclinical observations in humans suggest that resveratrol is safe and has potential in the treatment of obesity and insulin resistance in humans.

In particular, it improves insulin sensitivity, which might be due to a resveratrol-induced decrease in oxidative stress that leads to a more efficient insulin signalling via the Akt pathway. Studies on toxicity of resveratrol in humans demonstrated that this compound is well tolerated and no adverse effect has been found with higher dosage (5g/day). Resveratrol is available to people over-the-counter in health food stores and the internet as a dietary supplement. In humans, resveratrol is efficiently absorbed after oral administration; however, rapid phase II metabolism drastically limits its plasma bio-availability. The high concentrations of resveratrol in colorectal tissues, in excess of that required for activity in vitro, supports the colon as a target organ. The efficacy of resveratrol in other tissues may be largely dependent on whether its metabolites have significant activity or are able to regenerate resveratrol either locally or systemically (e.g. some metabolites, mainly sulfate-conjugated resveratrol, show biological effects in cellular models).

There are only a few studies evaluating the anti-inflammatory properties of resveratrol in humans. An extract of Polygonum Cuspidatum containing resveratrol given for 6-weeks to 10 healthy subjects was able to significantly suppress plasma concentrations of inflammatory cytokines (C-reactive protein, interleukin-6, tumor necrosis factor-α). Similarly, a nutritional supplement containing resveratrol plays an acute antioxidant and antiinflammatory effects in the postprandial state after a high-fat, high-carbohydrate meal in 10 healthy females.

The anti-inflammatory and antioxidant effects of resveratrol may be particularly interesting for smokers. Resveratrol increases the NO bioavailability and the inhibition of cyclooxygenase and 5-lipoxygenase activity of Cox-1 and it prevents the vascular leucocyte migration into damaged organs by decreasing the expression of endothelial vascular adhesion molecules and of pro-inflammatory genes. The inflammatory responses induced by oxidized LDL (low-density lipoproteins) are partially avoided by the addition of reveratrol and the authors concluded that it could affect vascular inflammation or/and injury not only as antioxidant, but also as modulator of inflammatory redox signalling pathways.

However, there are currently no published demonstrations of therapeutic or protective effects of resveratrol in appropriately designed clinical trials.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • age 20-50 years
  • actual smoking (≥5 cigarettes/die)
  • mean alcohol consumption <30g/day
  • absence of known hyperglycaemia, hypertension, cardiovascular disease, impaired renal function, liver disease, or any other systemic conditions -no use of any drug -oestrogen excluded-
  • not being on a particular diet and/or vitamin or other nutrient or integrator supplementation during the least 6-months

排除标准

  • actual pregnancy -known hyperglycaemia, hypertension, cardiovascular disease, impaired renal function, liver disease, or any other systemic chronic or acute conditions, use of any drug -oestrogen excluded-
  • being on a particular diet and/or vitamin or other nutrient or integrator supplementation during the last six months
  • mean alcohol consumption ≥30g/day
  • body mass index (BMI)>30 kg/m2
  • subject unable to give his/her informed consent.

结局指标

主要结局

C-reactive protein

时间窗: At baseline and every 30 days for three months

To evaluate before-after changes in circulating concentrations of C-reactive protein (CRP), an inflammation marker, in smokers submitted to resveratrol supplementation when compared to smokers treated with placebo

次要结局

  • tumor necrosis factor-α(At baseline and every 30-days for three months)
  • TAS (total antioxidant status)(At baseline and every 30-days for three months)
  • 4-hydroxynonenal(At baseline and after 30-days for three months)
  • nitrotyrosine(At baseline and every 30-days for three months)
  • endothelial nitric oxide synthase (eNOS)-polymorphism(At baseline and every 30-days for three months)
  • superoxide dismutase (SOD2)-polymorphism(At baseline and every 30-days for three months)
  • catalase-polymorphism(At baseline and every 30-days for three months)
  • interleukin-6(At baseline and every 30-days for three months)
  • pentraxin 3(At baseline and every 30-days for three months)

研究者

发起方
University of Turin, Italy
申办方类型
Other
责任方
Principal Investigator
主要研究者

Simona Bo

MD, Department of Internal Medicine

University of Turin, Italy

研究点 (2)

Loading locations...

相似试验